Breaking News!
FDA approved an extended-release formulation of carbidopa and levodopa for Parkinson’s disease, combining immediate-release granules and extended-release pellets.
FDA approved an extended-release formulation of carbidopa and levodopa for Parkinson’s disease, combining immediate-release granules and extended-release pellets.
The new formulation provides longer “Good On” time and less frequent dosing, addressing motor fluctuations and improving symptom control.
The RISE-PD trial showed significant improvements in “Good On” time and reduced off-time, with fewer treatment-emergent adverse events.This advancement simplifies dosing regimens and enhances therapeutic effects, marking a significant step forward in Parkinson’s disease management. 
–
Official Website: https://tinyurl.com/Parkinsons-Health
.
.
.
.
